Objective: The efficacy and safety of human chorionic gonadotropin (hCG)/Menotropin (hMG) and gonadotropin-releasing hormone (GnRH) pump in male adolescents with congenital hypogonadotropic hypogonadism were compared. As a possible clinical treatment program, it was proved being feasibility.
Methods: A prospective and non-randomized cohort control trial was conducted in male adolescents congenital hypogonadotropic hypogonadism (CHH) patients. The treatment was divided into study (0-3 months) and extension (3-12 months) periods. The testicular volume (TV), penis length (PL) and diameter (PD), and sex hormone levels were compared between the two groups during the treatment.
Results: After 3 months of treatment, the TV of hCG/hMG and GnRH groups increased to 5.1±2.7 mL (from 2.5±1.3 mL) vs 4.6±2.7 mL (from 2.7±1.5 mL), respectively (p ˃ 0.05). PL reached to 6.9±1.7cm (from 4.6±1.4cm) vs5.1±1.6cm (from 4.3±1.4cm) (p<0.05). PD were 2.5±0.5cm (from 1.6±0.4cm) vs1.9±0.6cm (from 1.5±0.5cm) (p<0.05). Testosterone was 459±163 (from 21.5±8.3) VS 99±95 ng/dL (from 20.7±6.0 ng/dL) . Their PL, PD, and testosterone of the hCG/hMG group were still significantly higher than those of GnRH group (18 cases), yet, TV was not different (p ˃ 0.05) in the expansion period (after 6-month treatment) in 8 cases. However, except testosterone was still higher in hCG/hMG group (p<0.05), other indices did not show and statistical difference (p ˃ 0.05) after 9-month treatment.
Conclusion: The hCG/hMG treatment is feasible. The initial 3 months could be used as a window to observe the treatment effectiveness. The long-term effectiveness, strengths, and weaknesses of it require further research.